Predicting nasal polyp return in people with aspirin-exacerbated respiratory disease
Biomarkers predicting nasal polyp recurrence in aspirin-exacerbated respiratory disease
This project looks for proteins and immune signals in nasal tissue and mucus that could predict whether nasal polyps will come back after surgery and aspirin desensitization in adults with aspirin-exacerbated respiratory disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11252885 on NIH RePORTER |
What this research studies
If I join, doctors will collect nasal fluid and sinus tissue from adults with aspirin-exacerbated respiratory disease who have had endoscopic sinus surgery and aspirin desensitization. The team will run proteomic, lipidomic, and cellular tests to measure both Type 2 (T2) and non-T2 inflammatory markers, including proteins like oncostatin M, interleukin-10, and macrophage colony-stimulating factor. Researchers will compare marker patterns in people whose polyps return quickly versus those who remain polyp-free after treatment. The aim is to identify a marker combination that can signal who is most likely to experience rapid polyp regrowth.
Who could benefit from this research
Good fit: Ideal candidates are adults (21+) with aspirin-exacerbated respiratory disease who have undergone endoscopic sinus surgery and aspirin desensitization and remain at risk for polyp recurrence.
Not a fit: People without AERD, those under 21, or those who have not had sinus surgery and aspirin desensitization are unlikely to be helped by this research.
Why it matters
Potential benefit: If successful, the findings could help predict which patients are at high risk of polyp recurrence and guide more personalized treatment after surgery.
How similar studies have performed: Prior work shows aspirin desensitization prevents recurrence for some patients and separate studies have linked T2 markers to nasal polyps, but combining T2 and non-T2 proteomic and lipidomic markers to predict recurrence is relatively novel.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Buchheit, Kathleen Mary — Brigham and Women's Hospital
- Study coordinator: Buchheit, Kathleen Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.